Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease

Shepherd, James; Kastelein, John J. P.; Bitfner, Vera A.; Carmena, Rafael; Deedwania, Prakash C.; Breazna, Andrei; Dobson, Stephen; Wilson, Daniel J.; Zuckerman, Andrea L.; Wenger, Nanerfe K.
August 2008
Mayo Clinic Proceedings;Aug2008, Vol. 83 Issue 8, p870
Academic Journal
OBJECTIVE: To investigate the effect of Intensive lipid lowering with high-dose atorvastatin on the incidence of major cardiovascular events compared with low-dose atorvastatin in patients with coronary artery disease and type 2 dIabetes, with and without chronic kidney disease (CKD). PATIENTS AND METHODS: Following 8 weeks' open-label therapy with atorvastatin (10 mg/d), 10,001 patients with coronary artery disease were randomized to receive double-blind therapy with either 80 mg/d or 10 mg/d of atorvastatin between July 1, 1998, and December 31, 1999. Of 1501 patients with diabetes, renal data were available for 1431. Patients with CKD were defined as having a baseline estimated glomerular filtration rate (eGFR) below 60 mL/min per 1.73 m², using the Modification of Diet in Renal Disease equation. RESULTS: After a median follow-up of 4.8 years, 95(17.4%) of 546 patients with diabetes and CKD experienced a major cardiovascular event vs 119(13.4%) of 885 patients with diabetes and normal eGFRs (hazard ratio [HR], 1.32; 95% confidence interval [Cl], 1.00-1.72; P<.05). Compared with 10 mg of atorvastatln, 80 mg of atorvastatin reduced the relative risk of major cardiovascular events by 35% in patients with diabetes and CKD (20.9% [57/273] vs 13.9% [38/273]; HR, 0.65; 95% Cl, 0.43-0.98; P=.04) and by 10% in patients with diabetes and normal eGFR (14.1% [62/441] vs 12.8% [57/444]; HR, 0.90; 95% Cl, 063-1.29; P=.56). The absolute risk reduction In patients with diabetes and CKD was substantial, yielding a number needed to treat of 14 to prevent 1 major cardiovascular event over 4.8 years. Both treatments were well tolerated. CONCLUSION: Patients with diabetes, stable coronary artery disease, and mild to moderate CKD experience marked reduction in cardiovascular events with Intensive lipid lowering, in contrast to previous observations in patients with diabetes and end-stage renal disease.


Related Articles

  • Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Jones, Camille A.; Krolewski, Andrzej S.; Rogus, John; Xue, Jay L.; Collins, Allan; Warram, James H. // Kidney International;May2005, Vol. 67 Issue 5, p1684 

    Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Background. The number of individuals initiating renal replacement therapy in the United States population grew exponentially over the past two decades. Cases of end-stage renal...

  • Effect of chronic renal failure on high-density lipoprotein kinetics. Fuh, Martin M. T.; C-Ming Lee; Chii-Y Jeng; Der-Chung Shen; Shyh-Ming Shieh; Reaven, Gerald M.; Y-D. Ida Chen // Kidney International;May1990, Vol. 37 Issue 5, p1295 

    Plasma lipid and lipoprotein concentration and high density lipoprotein (HDL) kinetics were determined in control subjects and patients with chronic renal failure (CRF). Results demonstrated that plasma triglyceride (TG) concentration was significantly higher (P < 0.001) in patients with CRF,...

  • Lipid peroxidation and antioxidant enzymes in children with chronic renal failure. Zwolińska, Danuta; Grzeszczak, Wiadystaw; Kiliś-Pstrusińska, Katarzyna; Szprynger, Krystyna; Szczepańska, Maria // Pediatric Nephrology;Aug2004, Vol. 19 Issue 8, p888 

    Increased lipid peroxidation (LP) has been observed in dialysis patients and in predialysis adults with advanced chronic renal failure (CRF). The aim of this study was to investigate whether predialysis CRF children have increased LP in plasma and red blood cells (RBC) and to evaluate the...

  • ROLUL LIPIDELOR ÃŽN PROGRESIA BOLII CRONICE DE RINICHI ÅžI TRATAMENTUL DISLIPIDEMIEI. Medrihan, Lǎcrǎmioara Solomia; Timofte, Delia; Ionescu, Dorin // Romanian Medical Journal;2008, Vol. 55 Issue 3, p179 

    CKD (Chronic kidney disease) is a new concept that uses the persistent injury of the kidney and GFR value to identify and classify patients. Below are presented on short the differences between the phases of chronic renal insufficiency and chronic kidney disease. There are described the factors...

  • Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. D.# Vaziri, Nosratola; Liang, Kaihui // Kidney International;Dec1996, Vol. 50 Issue 6, p1928 

    Chronic renal Failure (CRF) is associated with hypertriglyceridemia, impaired clearance of very low density lipoproteins (VLDL) and chylomicrons and their remnants as well as triglyceride-enrichment of various lipoproteins. These abnormalities are indicative of depressed lipoprotein lipase...

  • A Disease Haplotype for Advanced Nephropathy in Type 2 Diabetes at the ACE Locus. Ng, Daniel P. K.; Placha, Grzegorz; Serena Choo; Kee-seng Chia; Warram, James H.; Krolewski, Andrzej S. // Diabetes;Sep2006, Vol. 55 Issue 9, p2660 

    Previous investigations of the ACE gene as a susceptibility factor for diabetic nephropathy have primarily focused on its insertion/deletion (Ins/Del) polymorphism. In a departure from these earlier studies, we used three tagging markers (A-5466C, T-3892C, and Ins/Del) at the ACE locus to test...

  • Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. Bakris, G. L.; Toto, R. D.; McCullough, P. A. // Journal of Human Hypertension;Feb2005, Vol. 19 Issue 2, p139 

    Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The early stage of nephropathy is manifested by the presence of low levels of urinary albumin (microalbuminuria or urinary albumin excretion?30 and<299?mg/day). Albuminuria is a marker for development of nephropathy in...

  • Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. Meier, Juris J.; Nauck, Michael A.; Kranz, Daniel; Holst, Jens J.; Deacon, Carolyn F.; Gaeckler, Dirk; Schmidt, Wolfgang E.; Gallwitz, Baptist // Diabetes;Mar2004, Vol. 53 Issue 3, p654 

    Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential. Alterations of their secretion, in vivodegradation, and elimination in patients with chronic renal insufficiency (CRI)...

  • Diabetes and chronic kidney disease. Hall, Gwen // Practice Nurse;3/27/2009, Vol. 37 Issue 6, p32 

    The article presents an overview of the relationship which exists between type 2 diabetes and the development of chronic kidney disease. A discussion of guidelines which have been developed by Great Britain's Department of Health and which focus on renal investigations for people with diabetes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics